European Journal of Rheumatology
Literature Review

Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?

1.

UCB Pharma, Slough, UK

2.

Epi Excellence LLC, Garnet Valley, PA, USA

3.

Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, USA

Eur J Rheumatol 2023; 10: 39-44
DOI: 10.5152/eurjrheum.2023.22012
Read: 1205 Downloads: 404 Published: 01 January 2023

Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome.

Cite this article as: Ioannou Y, Beukelman T, Murray M, Erkan D. Incidence of antiphospholipid syndrome: Is estimation currently possible? Eur J Rheumatol. 2023;10(1):39-44.

Files
EISSN 2148-4279